Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Journal of Feline Medicine and Surgery

Volumn 20, Issue 4, 2018, Pages 378-392

  Pedersen, Niels C ^a   Kim, Yunjeong ^b   Liu, Hongwei ^a   Galasiti Kankanamalage, Anushka C ^c   Eckstrand, Chrissy ^d   Groutas, William C ^c   Bannasch, Michael ^a   Meadows, Juliana M ^a   Chang, Kyeong Ok ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

^c WICHITA STATE UNIVERSITY   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLOBULIN; PLASMA PROTEIN; PROTEINASE INHIBITOR; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOPSY; BLOOD CELL COUNT; BODY WEIGHT GAIN; CAT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EOSINOPHIL COUNT; FELINE INFECTIOUS PERITONITIS; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTOPENIA; MENINGOENCEPHALITIS; MONOCYTE; NEUTROPHIL; NONHUMAN; OPHTHALMOSCOPY; PHARMACOKINETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; VIRUS RESISTANCE; ANIMAL; DRUG EFFECT; FELINE CORONAVIRUS; FEMALE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CATS; CORONAVIRUS, FELINE; FELINE INFECTIOUS PERITONITIS; FEMALE; PROTEASE INHIBITORS; VIRUS REPLICATION;

EID: 85042533541     PISSN: 1098612X     EISSN: 15322750     Source Type: Journal    
DOI: 10.1177/1098612X17729626     Document Type: Article

References (28)

1. Prokofjeva MM, Kochetkov SN, Prassolov VS. Therapy of HIV infection: current approaches and prospects. Acta Naturae 2016; 8: 23–32.
2. Carter W, Connelly S, Struble K. Reinventing HCV treatment: past and future perspectives. J Clin Pharmacol 2017; 57: 287–296.
3. Kim Y, Lovell S, Tiew KC. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 2012; 86: 11754–11762.
4. Kim Y, Mandadapu SR, Groutas WC. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antiviral Res 2013; 97: 161–168.
5. Kim Y, Shivanna V, Narayanan S. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J Virol 2015; 89: 4942–4950.
6. Kim Y, Liu H, Galasiti Kankanamalage AC. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 2016; 12: e1005531.
7. Miller FG, Brody H. What makes placebo-controlled trials unethical? Am J Bioethics 2002; 2: 3–9.
8. Chiodo GT, Tolle SW, Bevan L. Placebo-controlled trials good science or medical neglect? West J Med 2000; 172: 271–273.
9. Van Kruiningen HJ, Ryan MJ, Shindel NM. The classification of feline colitis. J Comp Pathol 1983: 93: 275–294.
10. Pedersen NC, Eckstrand C, Liu H. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Vet Microbiol 2015; 175: 157–166.
11. Pellerin M, Lopez-Aquirre Y, Penin F. Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. J Virol 2004; 78: 4617–4627.
12. Pedersen NC, Allen CE, Lyons LA. Pathogenesis of feline enteric coronavirus infection. J Feline Med Surg 2008; 10: 529–541.
13. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963–2008. J Feline Med Surg 2009; 11: 225–258.
14. Pedersen NC. An update on feline infectious peritonitis: virology and immunopathogenesis. Vet J 2014; 201: 123–132.
15. Pedersen NC, Liu H, Durden M. Natural resistance to experimental feline infectious peritonitis virus infection is decreased rather than increased by positive genetic selection. Vet Immunol Immunopathol 2016; 171: 17–20.
16. Pedersen NC, Liu H, Gandolfi B. The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis. Vet Immunol Immunopathol 2014; 162: 33–40.
17. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008; 16: 94–98.
18. Foley JE, Lapointe JM, Koblik P. Diagnostic features of clinical neurologic feline infectious peritonitis. J Vet Intern Med 1998; 12: 415–423.
19. Mesquita LP, Hora AS, de Siqueira A. Glial response in the central nervous system of cats with feline infectious peritonitis. J Feline Med Surg 2016; 18: 1023–1030.
20. Pedersen NC. Feline infectious peritonitis: something old, something new. Feline Pract 1976; 6: 42–51.
21. Valcour V, Sithinamsuwan P, Letendre S. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8: 54–61.
22. Joseph SB, Arrildt KT, Sturdevant CB. HIV-1 target cells in the CNS. J Neurovirol 2015; 21: 276–289.
23. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disase: current issues in pathogenesis, diagnosis and treatment. Cold Spring Harb Perspect Med 2012; 2: a007120
24. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatology 2015; 7: 1617–1631.
25. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000; 78: 334–334.
26. Smyk-Pearson S, Tester IA, Klarquist J. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol 2008; 82: 1827–1837.
27. Legendre AM, Bartges JW. Effect of polyprenyl immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg 2009; 11: 624–626.
28. Legendre AM, Kuritz T, Galyon G. Polyprenyl immunostimulant treatment of cats with presumptive non-effusive feline infectious peritonitis in a field study. Front Vet Sci 2017; 4: 7.